Professional Services

DPEBB Professional Services Chart

This handy chart presents an overview of all current provincially funded services in Saskatchewan. You will find:

  • Descriptions,
  • Notes and limitations,
  • Service fees, and
  • PseudoDINS.

(Updated June 17, 2024) 

DPEBB-Professional-services-chart-with-PseudoDins-June-17-2024-Update


Direct Observed Therapy (DOT)

The Drug Plan and Extended Benefits Branch (DPEBB) will remunerate pharmacies for witnessing the administration of approved Hepatitis C medications to eligible patients. The purpose of this program is to optimize patient medication adherence by reducing the risk of treatment interruption for approved Hepatitis C medications.

DOT Policy 2017

#637 Pharmacy Information Bulletin April 2017.pdf

#645 Pharmacy Information Bulletin August 2017

#663 Pharmacy Information Bulletin April 2018

#165 Saskatchewan Formulary Bulletin April 2017.pdf

#170 Saskatchewan Formulary Bulletin April 2018 – Hepatitis C.pdf


Saskatchewan Medication Assessment Program (SMAP)

The Saskatchewan Medication Assessment Program or SMAP is a provincial program available to beneficiaries under the Drug Plan and Extended Benefits Branch (DPEBB) age 65 and older who are community-based, living in their own residence, taking five (5) or more chronic or taking an anticoagulant or taking a Beers List medication.

These patients may receive an annual medication assessment and if eligible and require, follow-ups and compliance packaging. Patients living in an approved private service home or group home are eligible for an annual medication assessment.

New Mandatory SMAP Documentation

The Ministry of Health recently announced changes to the Saskatchewan Medication Assessment Program (SMAP) documentation as noted in the #639 Pharmacy Information Bulletin – SMAP Documentation. These changes will become mandatory as of September 1, 2017. These new forms may be used effective immediately.  

You will be required to use the new forms (below) in order for your pharmacy to receive remuneration from the Drug Plan and Extended Benefits Branch (DPEBB) for conducting a medication assessment under SMAP. If you have your own forms, they must be approved by the DPEBB prior to use in order for the SMAP fees to be eligible for remuneration. All previously approved forms will need to be re-approved to ensure they meet the DPEBB’s current requirements of the program.

SMAP Policy 2017

2017 SMAP Documentation Forms Fillable

NEW SMAP Mandatory Documentation Forms (pdf format)


Pharmacist Guide to SMAP

The Pharmacist Guide to SMAP (the “Guide”) was developed by PAS and the staff at the Medication Assessment Centre (MAC) to support pharmacists and pharmacy students. The Guide showcases a stepwise approach to performing a medication assessment and demonstrates how the process can be applied to the new SMAP documentation forms (or any other medication assessment documentation).

Pharmacist Guide for SMAP


Updated Policy and Bulletins

#639 Pharmacy Information Bulletin May 2017

Please review the Medication Assessment Program Comparison Chart for eligibility.

Medication Assessment Program Comparison Chart

The practitioner communication letter form below is not mandatory. Pharmacists are permitted to use any format they choose for communicating with the practitioner.

SASK_Step 5_Practitioner Communication letter


Medication Assessment & Compliance Packaging Program (MACPP)

Eligible Drug Plan Extended Benefits Branch (DPEBB) beneficiaries may receive an annual medication assessment and compliance packaging if they are:

  • receiving homecare or mental health services, living in their own homes or
  • any patients living in an approved Community Living Service Delivery Group Homes (CLSD)

Please note: Although specific documentation is not mandatory, pharmacists are encouraged to use SMAP documentation for consistency.

Please review the MA Program Comparison Chart for Eligibility.

Medication Assessment Program Comparison Chart

Mental Health – MACCP Policy

Home Care – MACCP Policy

Home Care-Mental Health Request Form

CLSD MACCP Policy

Program overview for eligible clients living in a Community Living Service Delivery (CLSD) licensed group home or approved private service home


Minor Ailment Prescribing

Minor Ailment prescribing is a Level 1 Activity. Pharmacists providing minor ailment services to patients must follow the most recent Minor Ailment Guidelines and Documentation developed by medSask. Updates to Guidelines can happen at any time so check back often or subscribe to medSask News to receive email notifications.

Minor Ailments, Self-Care and Other Diseases Program Policy and Procedures

Please note: All Saskatchewan residents with a valid health card (including NIHB, DVA or other federal beneficiaries) are eligible to receive this billable service funded by the provincial Drug Plan.


Prescriptive Authority (Level 1) Prescribing

All other Level 1 activities including: Interim Supplies, Unable to Access Supplies, Emergency Supply, Missing Information, Alter Dosage Form and Drug Reconciliation Activities Billing Policy are referenced in the Drug Plan’s series of Prescriptive Authority for Pharmacists Pharmacy Information Bulletins:

#767 Pharmacy Information Bulletin June 2021

Therapeutic Substitution Prescriptive Authority

#942 Pharmacy Information Bulletin March 2011

#493 Pharmacy Information Bulletin March 2011

FAQ

Published March 31, 2011

#504 Pharmacy Information Bulletin January 2012

Policy on Narcotics and medications that do not require a prescription

Published January 1, 2012

In addition to a Special Edition PAS It On Bulleting #48, PAS also created a Guide and an FAQ made available below to PAS members:

Level 1 Prescriptive Authority Pharmacist Guide

Published April 2011

Prescriptive Authority FAQs

PAS It On #48 – Special Edition Prescriptive Authority

Program Overview

#493 Pharmacy Information Bulletin March 2011

Please note:

Details pertaining to Minor Ailment Prescribing are outdated in the above documents. For updated information, please refer to the Minor Ailments section on this Professional Services page.

 


PACT is a tobacco cessation program available to beneficiaries of the provincial Drug Plan. It incorporates Prochaska’s “Stage of Change” theory and principles of Motivational Interviewing to support patients through their quit journey. Click here for more pharmacist and patient materials to support the delivery of the program. 

PAS in partnership with CPDPP and the SCA has updated PACT 1 & 2, the Oncology, and the Indigenous Tobacco training modules. The updated training modules are available on the USask CPE website. The updated training is free for all Saskatchewan pharmacists and pharmacy students. 

*Please note: certification is required for any PACT counseling that is Bronze Plus and up*

Mandatory Documentation

The PACT forms below have been developed by PAS to fulfill the documentation requirements of the PACT Policy and Procedure. All forms are mandatory if billing the Drug Plan.

Please note:

Documentation other than the forms produced by PAS must be approved by the Drug Plan to prevent audit clawback.

STEP 1 – Bronze-Bronze Plus

STEP 2 – Patient Assessment

Includes:

  • 2A – Cessation of Tobacco, and
  • 2B – Review of Patient’s Smoking/Tobacco Use

STEP 3 – Personalized Care Plan

STEP 4 – Practitioner Communication Letter

STEP 5 – Group Session Individual Consent and Registration

Billing Policy

The complete policy and procedure requirements of the program including beneficiaries, pseudoDINS, and program limitations can be found in the documents below.

All policy and procedure documents can also be found in the Bulletins page on the Drug Plan WEB page, accessible only in community pharmacies.

PACT Policy & Procedure

Published June 3, 2009
Updated October 1, 2013

#546 Pharmacy Information Bulletin September 2013

Published September 26, 2013

 


Seamless Care

Pharmacies may charge a fee when a pharmacist provides seamless care services to a patient who is transferred from an institution to a community setting, in accordance with the Drug Plan’s Seamless Care Policy

#416 Pharmacy Information Bulletin April 2007

Seamless Care Policy

Published April 2007

A Trial Policy Document – Appendix B


Trial Prescription Program (TPP)

A pharmacy may charge a fee to the Drug Plan when a patient is enrolled in the TPP for eligible drugs, and Trial Prescription Program Policy is followed.

Trial Prescription Program Policy

Published July 2007

A Trial Policy Document – Appendix B


Refusal To Dispense

A pharmacy may charge a fee to the Drug Plan when refusing to dispense eligible prescriptions meeting specific criteria as per the Refusal To Dispense Fee Policy.

Refusal to Dispense Fee Policy

Published April 2007

A Trial Policy Document – Appendix B 


Methadone Managed Care

A managed care fee may be charged to the Drug Plan for patients receiving methadone for opioid addition as per the Methadone for the Management of Opioid Addictions Policy.

#612 Pharmacy Information Bulletin May 2016 – Methadone and Suboxone Billing Process


COVID-19 Antivirals

PaxlovidTM Limited Access EDS Updates June 2024

Limited Access Exception Drug Status (EDS) Application June 3 2024

Limited Access Exception Drug Status (EDS) Application Q and A June 3 2024

#889 Paxlovid Limited Access EDS Application (LAEA)


COVID-19 Antiviral policies have been updated, and prescribing criteria should refer to the most up-to-date documentation provided by the Ministry of Health. The following documents are maintained for your information as they provide useful information on resources and maintaining involvement with the PaxlovidTM program in Saskatchewan.

Pharmacy FAQs #2 on PaxlovidTM

Paxlovid Distribution, Prescribing, and Assessment Policy

Evushelf For The Preventions of COVID-19 June 2022 Bulletin

Pharmacy FAQs on Paxlovid


Take Home Naloxone Program

Take Home Naloxone Fee Claims Procedure

Take Home Naloxone Policy


Biosimilar Insulin Transition Fee 

Biosimilar Insulin Transition Fee Bulletin 838

Letter to Healthcare Providers – Saskatchewan Biosimilars Initiative – Biosimilar Insulin Coverage Reminders and Updates

Members Memo – Biosimilars Transition